<DOC>
	<DOCNO>NCT02651753</DOCNO>
	<brief_summary>This study randomize , open-label , single oral dose , 2-way crossover clinical trial compare safety pharmacokinetics CKD-337 healthy male volunteer .</brief_summary>
	<brief_title>A Clinical Trial Compare Safety Pharmacokinetic Characteristics CKD-337</brief_title>
	<detailed_description>This study randomize , open-label , single oral dose , 2-way crossover clinical trial compare safety pharmacokinetics CKD-337 healthy male volunteer . Subjects receive either single oral dose test formulation ( CKD-337 ) oral dose reference formulation ( Lipitor+Lipidil supra ) . Each treatment period separate washout period least 7 day .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1 . Healthy male old 19 year time screen 2 . BMI 17.5~30.5 kg/m2 body weight 55kg 3 . Subject chronic disease , symptoms pathological finding 4 . Suitable subject determine laboratory test ( hematology test , blood chemistry , urinalysis test ) accord characteristic drug ECG test time screen 5 . Subject fully understand clinical trial indepth explanation , decide join clinical trial sign inform consent 1 . Subject history hepatic , kidney , neurological , respiratory , endocrine , hematooncology , urinary , cardiovascular , musculoskeletal psychiatric disease clinically significant follow history 1 ) Gallbladder disease include cholelithiasis , severe hepatic impairment 2 ) Acute/chronic pancreatitis due hypertriglyceridemia 3 ) Pulmonary embolism interstitial lung disease 4 ) Genetic problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 5 ) Hypoalbuminemia 6 ) Alcoholics 7 ) Predisposition rhabdomyolysis 2 . Subject history gastrointestinal disease gastrointestinal surgery affect drug absorption 3 . Subject hypersensitivity drug composition contain choline fenofibrate , fenofibrate atorvastatin , drug ( aspirin , fenofibrate series , antibiotic ) 4 . The following clinical significant finding time screen QTc &gt; 450ms PR interval &gt; 200msec QRS duration &gt; 120msec 5 . The following result clinical laboratory test CPK &gt; 2 x upper limit normal range Liver function test ( AST , ALT , ALP , Total bilirubin , γGT ) &gt; 2 x upper limit normal range eGFR ( estimate GFR ) &lt; 60 mL/min/1.73m2 6 . Systolic blood pressure ≥ 160mmHg ≤ 100mmHg , Diastolic blood pressure ≥ 95mmHg ≤ 60mmHg time screen 7 . History drug abuse positive reaction drug abuse screen test urine 8 . Taking ETC , oriental medicine within 2 week OTC , vitamin within 1 week first dose 9 . Taking medication involve clinical trial within 3 month first dose 10 . Whole blood donation 2 month component blood donation within 1 month blood transfusion within 1 month first dose 11 . Alcohol &gt; 21 units/week ( 1unit=10g pure alcohol ) , within 6 month first dose 12 . Smoker ( &gt; 10 cigarettes/day ) last 3 month 13 . Comsumption grapefruit food contain grapefruit clinical trial period first dose 48hours ago 14 . Comsumption food contain caffeine ( e.g . coffee , green tea ) 24 hour ago IP dose discharge 15 . Not use reliable contraception , plan pregnancy study 16 . An impossible one participate clinical trial investigator 's decision include laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>